Amylyx Pharmaceuticals, Inc.(NASDAQ : AMLX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.23%||170.71||0.7%||$966.95m|
|LLY||Eli Lilly & Co.||0.47%||302.72||1.1%||$749.66m|
|MRK||Merck & Co., Inc.||1.30%||88.55||0.7%||$749.54m|
|BMY||Bristol-Myers Squibb Co.||2.14%||73.67||1.0%||$663.79m|
|SIGA||SIGA Technologies, Inc.||-5.19%||22.09||0.0%||$391.42m|
|ALNY||Alnylam Pharmaceuticals, Inc.||5.24%||230.04||8.1%||$253.91m|
|HZNP||Horizon Therapeutics Plc||1.01%||70.30||5.4%||$199.78m|
|NVO||Novo Nordisk A/S||-0.67%||102.51||0.1%||$151.88m|
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.